The prognostic value of stromal FK506‐binding protein 1 and androgen receptor in prostate cancer outcome. Issue 2 (8th October 2016)

• Record Type: Journal Article
• Authors: Leach, Damien A.; Trotta, Andrew P.; Need, Eleanor F.; Risbridger, Gail P.; Taylor, Renea A.; Buchanan, Grant
• Is Part Of: Prostate. Volume 77:Issue 2(2017)
• Page Start: 185
• Page End: 195
• Publication Date: 2016-10-08
• Subjects: prostate cancer -- FK506‐binding protein 1 -- androgen receptor -- stroma -- fibroblasts; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23259
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract : BACKGROUND: Improving our ability to predict cancer progression and response to conservative or radical intent therapy is critical if we are to prevent under or over treatment of individual patients. Whereas the majority of solid tumors now have a range of molecular and/or immunological markers to help define prognosis and treatment options, prostate cancer still relies mainly on histological grading and clinical parameters. We have recently reported that androgen receptor (AR) expression in stroma inversely associates with prostate cancer‐specific survival, and that stromal AR reduces metastasis. For this paper, we tested the hypothesis that the AR‐regulated gene FKBP51 could be used as a marker of AR activity to better predict outcome. METHODS: Using immunohistochemistry on a cohort of 64 patient‐matched benign and malignant prostate tissues, we assessed patient outcome by FKBP51 and AR levels. Immunoblot and RT‐qPCR were used to demonstrate androgen regulation of FKBP51 in primary and primary human prostatic fibroblasts and fibroblast cell‐lines. RESULTS. As predicted by FKBP51 level, high AR activity in cancer stroma was associated with longer median survival (1, 306 days) compared with high AR alone (699 days), whereas those with low AR and/or low FKBP51 did poorly (384 and 338 days, respectively). Survival could not be predicted on the basis cancer epithelial AR levels or activity, and was not associated with immunoreactivity in patient matched benign tissues. CONCLUSION: FKBP51 improves the ability of stromal AR to predict prostate cancer‐specific mortality. By adding additional immunological assessment, similar to what is already in place in a number of other cancers, we could better serve patients with prostate cancer in prognosis and informed treatment choices. Prostate 77:185–195, 2017 . © 2016 Wiley Periodicals, Inc.